Healthcare / Medical Instruments & SuppliesHKSE
$0.08
-0.00 (-1.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-46.7M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$418M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-11.6%
↓Gross Margin
36.4%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
-9.7%
FCF CAGR
—
FCF margin
-42.0%
FCF / Net income
1.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $139.1M · net income $-46.7M · FCF $-58.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $139.1M | $139.1M | $185.4M | $185.9M | $191.5M | $209.6M |
| Net Income | $-46.7M | $-46.7M | $-46.4M | $7.5M | $-123.3M | $2.4M |
| EBITDA | $-33.4M | $-33.4M | $-32.7M | $27.6M | $-131.9M | $46.8M |
| EPS | -0.01 | -0.01 | -0.01 | 0.00 | -0.02 | 0.00 |
| Gross Margin | 36.4% | 36.4% | 44.2% | 43.6% | 43.1% | 46.5% |
| Operating Margin | -37.6% | -37.6% | -12.6% | -22.0% | -33.7% | -26.7% |
| Net Margin | -33.6% | -33.6% | -25.0% | 4.0% | -64.4% | 1.1% |
| Balance Sheet | ||||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.04 | 0.07 | 0.05 |
| Current Ratio | 3.98 | 3.98 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-58.4M | $-58.4M | $-39.1M | $-46.7M | $-72.6M | $-162.4M |
| Returns | ||||||
| ROE | -11.6% | -11.6% | -10.8% | 1.5% | -25.4% | 0.4% |
| Valuation | ||||||
| P/E | — | — | — | 22.00 | — | 164.00 |
| EV/EBITDA | — | — | — | 0.37 | — | 3.99 |
| P/B | 1.04 | 1.04 | 0.28 | 0.34 | 0.76 | 0.63 |
| Growth & Yield | ||||||
| Revenue Growth | -24.9% | -24.9% | -0.3% | -2.9% | — | — |
| EPS Growth | -1.1% | -1.1% | -713.3% | 106.1% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+418.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.01
Residual
+418.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.